跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 23,162 条关于
“DESTINY-Breast04”
全部
23,162
临床试验
21,629
药物
81
机构
21
资讯
1,431
4年前
FDA Grants Breakthrough Therapy Designation to Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer
去年
Enhertu Wins 2024 Prix Galien USA Award for Best Biotechnology Product
去年
T-DXd Shows Promise in HER2-Ultra Low Breast Cancer, Expanding Treatment Horizons
去年
Seagen Wins $42M Patent Verdict Against Daiichi Sankyo Over Enhertu Breast Cancer Drug
去年
Advancements in Targeted Therapies Improve Survival in Breast Cancer
3年前
Next-Generation ADCs and SERDs Transform Breast Cancer Treatment Landscape
5年前
Phase 3 DESTINY-Breast05 Trial Compares Trastuzumab Deruxtecan to T-DM1 in High-Risk HER2+ Early Breast Cancer
前天
Enhertu Cuts Progression Risk 37% in First-Line HER2-Mutant NSCLC, Delivering 14.3-Month Median PFS in DESTINY-Lung04
9个月前
DESTINY-Ovarian01 Phase 3 Trial Launches to Test ENHERTU as First-Line Maintenance Therapy for HER2-Expressing Ovarian Cancer
去年
Trastuzumab Deruxtecan Extends Survival in HER2-Positive Breast Cancer with Brain Metastases
第 1 页,共 144 页
上一页
下一页